Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.86 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.86 |
| ▸ | GAK | O14976 | 1/20 | 0.86 |
| ▸ | FES | P07332 | 1/20 | 0.86 |
| ▸ | FER | P16591 | 1/20 | 0.86 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.86 |
| ▸ | TEC | P42680 | 1/20 | 0.86 |
| ▸ | CLK1 | P49759 | 1/20 | 0.86 |
| ▸ | JAK3 | P52333 | 1/20 | 0.86 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.86 |
| ▸ | BTK | Q06187 | 1/20 | 0.86 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29229023 | 0.97 | ALK (0.81) | EGFRALKGAKFESFER | |
| SCHEMBL30221516 | 0.97 | ALK (0.81) | EGFRALKGAKFESFER | |
| Rociletinib SCHEMBL4177736 | 0.93 | EGFR (1.00) | EGFRALKGAKFESFER | |
| Rociletinib SCHEMBL29448192 | 0.93 | EGFR (1.00) | EGFRALKGAKFESFER | |
| Rociletinib SCHEMBL29350136 | 0.93 | EGFR (1.00) | EGFRALKGAKFESFER | |
| SCHEMBL17531020 | 0.92 | ALK (0.83) | EGFRALKGAKFESFER | |
| Rociletinib SCHEMBL30101824 | 0.92 | EGFR (0.99) | EGFRALKGAKFESFER | |
| SCHEMBL17531019 | 0.92 | EGFR (0.81) | EGFRALKGAKFESFER | |
| SCHEMBL24413852 | 0.91 | EGFR (0.86) | EGFRALKGAKFESFER | |
| SCHEMBL4166347 | 0.90 | EGFR (1.00) | EGFRALKGAKFESFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881664-B2 | Methods for treating EGFR mutant cancers | NOVARTIS AG (CH) | 2021-01-05 | — | — | US | disclosed |
| US-10005738-B2 | Salts of an epidermal growth factor receptor kinase inhibitor | CELGENE CAR LLC (BM) | 2018-06-26 | — | — | US | disclosed |
| WO-2016029002-A2 | GROWTH FACTOR RECEPTOR INHIBITORS | CLOVIS ONCOLOGY, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005738-B2 | Salts of an epidermal growth factor receptor kinase inhibitor | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 59/4885GAK 407/4885 |
| US-10881664-B2 | Methods for treating EGFR mutant cancers | EGFR, ERBB2, ERBB3 | EGFR 1/4885ALK 15/4885GAK 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.